About: Chinese medical drugs for coronavirus disease 2019: A systematic review and meta-analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chinese medical drugs for coronavirus disease 2019: A systematic review and meta-analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Chinese medical drugs for coronavirus disease 2019: A systematic review and meta-analysis
Creator	Li, Nan Zhang, Junhua Jin, Xinyao Li, Liu Pang, Bo Yang, Fengwen Zheng, Wenke Li, N Liu, Zhi Pang, Wentai Li, Yuyun
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Integration of Chinese medical drugs (CMD) and western medicine (WM) has been widely used in the treatment of Coronavirus Disease 2019 (COVID-19). This systematic review aimed to evaluate the efficacy and safety of CMD for COVID-19. METHOD: A literature search was performed in six databases from injection to June 2020. Both randomized controlled trials (RCTs) and quasi-RCTs were considered as eligible. The quality of included RCTs were assessed by Cochrane Risk of Bias Tool, and Review Manager 5.3 software was used to do meta-analysis. RESULT: Eleven studies with 1259 patients were included in this study. CMD included herbal decoction and Chinese patent medicine. The methodological quality was evaluated as generally unclear. The results of meta-analysis showed that the integration of CMD and WM had better efficacy than WM in number of patients turned to severe and critical type (RR = 0.47, 95% CI=[0.32, 0.69], P < 0.0001), length of hospital stay (MD= -7.95, 95% CI=[-14.66, -1.24], P = 0.02), defervescence time (MD= -1.20, 95% CI=[-2.03, -0.38], P = 0.004), cough resolution rate (RR = 1.37, 95% CI=[1.15, 1.64], P = 0.0004), fatigue resolution rate (RR = 1.37, 95% CI=[1.02, 1.83], P = 0.04), and tachypnea resolution rate (RR = 2.20, 95% CI=[1.11, 4.39], P = 0.02). As for safety, there was no significant difference between two groups. CONCLUSION: CMD may bring potential benefit to patients suffered from COVID-19. However, the quality of included trials is not good enough. High quality study with core outcome set are still required.
has issue date	2020-07-28(xsd:dateTime)
bibo:doi	10.1016/j.imr.2020.100477
bibo:pmid	32834992
has license	no-cc
sha1sum (hex)	eb4b3bf90931706d44b0a97e41da46876e188f0d
schema:url	https://doi.org/10.1016/j.imr.2020.100477
resource representing a document's title	Chinese medical drugs for coronavirus disease 2019: A systematic review and meta-analysis
has PubMed Central identifier	PMC7385501
has PubMed identifier	32834992
schema:publication	Integr Med Res
resource representing a document's body	covid:eb4b3bf90931706d44b0a97e41da46876e188f0d#body_text
is schema:about of	named entity 'evaluate' named entity 'Integration' named entity 'CMD' named entity 'systematic review' named entity 'meta-analysis' named entity 'coronavirus disease 2019' covid:arg/eb4b3bf90931706d44b0a97e41da46876e188f0d named entity 'systematic review' named entity 'COVID-19' named entity 'COVID-19' named entity 'Coronavirus Disease 2019' named entity 'systematic review' named entity 'coronavirus disease 2019' named entity 'medical drugs' named entity 'meta-analysis' named entity 'China' named entity 'meta-analysis' named entity 'RCTs' named entity 'COVID-19' named entity 'adverse events' named entity 'symptom' named entity 'PROSPERO' named entity 'metabolic acidosis' named entity 'coronavirus' named entity 'random effect' named entity 'septic shock' named entity 'gastrointestinal' named entity 'nausea' named entity 'TCM' named entity 'Allocation concealment' named entity 'clinical symptom' named entity 'clinical trials' named entity 'meta-analysis' named entity 'medical drugs' named entity 'COVID-19' named entity 'detection bias' named entity 'viruses' named entity 'observational studies' named entity 'clinical symptoms' named entity 'National Administration of Traditional Chinese Medicine' named entity 'systematic reviews' named entity 'COVID-19' named entity 'publication bias' named entity 'RCTs' named entity 'Core outcome' named entity 'disease control' named entity 'core outcome' named entity 'attrition bias' named entity 'funnel plot' named entity 'COVID-19' named entity 'China' named entity '2019-nCoV' named entity 'clinical features' named entity 'acid-base' named entity 'cough' named entity 'sample size' named entity 'pruritus' named entity 'clinical trials' named entity 'western medicine' named entity 'Selective reporting' named entity 'systematic reviews' named entity 'confidence intervals' named entity 'fatigue' named entity 'COVID' named entity 'loss of appetite' named entity 'hypoxia' named entity 'all-cause' named entity 'COVID-19' named entity 'inter-study heterogeneity' named entity 'Treatment group' named entity 'organ failure'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software